NCT04939454Befejeződött
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 1.
Rövid összefoglaló (regiszter, angolul)
Chronic obstructive pulmonary disease (COPD) is presently the third leading cause of death worldwide and is characterized by irreversible airflow limitation diagnosed by spirometry. COPD is currently considered as a systemic disease with predominantly respiratory involvement, associated with numerous comorbidities. Among these, muscle wasting, present in about one third of patients, is associated with a higher mortality (up to 10-fold, irrespective of the severity of the obstruction). Muscle wasting is classically characterized by a decrease in muscle strength and volume (sarcopenia), which can be defined by a decrease in the muscle mass measured by dual X-ray absorptiometry: Appendicular Skeletal Muscle Mass or ASM / height < 7.0 kg/m2 in men and 5.5 kg/m2 in women. However, sarcopenia is largely underestimated in current clinical practice. Moreover, there is no specific treatment: only exercise training as part of respiratory rehabilitation has shown some efficiency. The underlying pathophysiological mechanisms are indeed poorly characterized. Fibrocytes, cells derived from blood monocytes and able to migrate to different organs in order to play pro-fibrotic or pro-inflammatory roles, play a key role in bronchial obstruction. They are recruited in the blood of COPD patients during an acute exacerbation according to a CXCL12/CXCR4 chemotactic axis. Their role in COPD sarcopenia is currently unknown, but recent data show that they are involved in a mouse model of muscular dystrophy. The hypothesis is that fibrocytes are involved in COPD sarcopenia.
- Állapot (regiszter)
- Befejeződött
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 22 (tényleges)
- Első benyújtás
- 2021. jún. 11.
- Kezdés
- 2022. nov. 29.
- Elsődleges befejezés
- 2025. nov. 21.
- Fő szponzor
- University Hospital, Bordeaux
- Betegségek
- Krónikus obstruktív tüdőbetegség (COPD)
- NCT-szám
- NCT04939454
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Bevont résztvevők: 22
- 2022. nov. 29. és az elsődleges befejezés (2025. nov. 21.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Other concomitant respiratory pathology (e.g., asthma);
- Current systemic corticosteroid therapy;
- Presence of a concomitant muscular pathology, innate (e.g. genetic myopathy) or acquired (e.g. myositis);
Más betegség
- Acute exacerbation of COPD or acute intercurrent condition (e.g. infection) ongoing or resolved within the last 48 hours
- Progressive bronchopulmonary cancer;
- Disorders of hemostasis detected on the blood sample;
Laborértékek
- Contraindication to muscle biopsy: acquired or innate hemostasis disorders, anticoagulant therapy or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias;
Egyéb
- Pregnant or breast-feeding woman;
- Patient undergoing respiratory rehabilitation;
- Refusal to participate in the study.
- Pregnancy in progress.
Kiket keres a vizsgálat
- Men or women 40 years of age or older;
- Diagnosed with COPD according to the 2018 Global Initiative for Lung Disease (GOLD) criteria:
- Smoking intoxication greater than or equal to 10 pack-years
- Bronchial obstruction on spirometry with a FEV1 to FVC ratio post-bronchodilator < 70%.
- Available measurement of lean body mass by bioelectrical impedancemetry performed as part of routine care;
- Insured under the French social security system;
- Informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
- The patients included will be sarcopenic and non-sarcopenic (equal numbers in each group, patients categorized according to the result of dexametry), and will be matched on sex and age (± 5 years).
Életkor a regiszterben: 40 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Hopital Haut Leveque Chu de Bordeaux | Pessac | Franciaország | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.